Spotlight: ICN Acquires Global Rights to 4 Roche Drugs

ICN Pharmaceuticals Inc., moving to offset business setbacks in Eastern Europe, said it’s buying global rights to four medicines from Swiss drug giant Roche Holdings for $179 million in cash and stock. Costa Mesa-based ICN is acquiring rights to Dalmodorm, a drug for sleep disorders; Fluoro-Uracil, a treatment for cancer; Librax, for gastrointestinal disorders; and Mogadon, a sleep-disorder drug used to treat epilepsy. The drugs are expected to generate sales of about $67 million a year.